SG10202011023YA - Dna monoclonal antibodies targeting il-6 and cd126 - Google Patents
Dna monoclonal antibodies targeting il-6 and cd126Info
- Publication number
- SG10202011023YA SG10202011023YA SG10202011023YA SG10202011023YA SG10202011023YA SG 10202011023Y A SG10202011023Y A SG 10202011023YA SG 10202011023Y A SG10202011023Y A SG 10202011023YA SG 10202011023Y A SG10202011023Y A SG 10202011023YA SG 10202011023Y A SG10202011023Y A SG 10202011023YA
- Authority
- SG
- Singapore
- Prior art keywords
- monoclonal antibodies
- antibodies targeting
- dna monoclonal
- dna
- targeting
- Prior art date
Links
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332377P | 2016-05-05 | 2016-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202011023YA true SG10202011023YA (en) | 2020-12-30 |
Family
ID=60203626
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202011023YA SG10202011023YA (en) | 2016-05-05 | 2017-05-05 | Dna monoclonal antibodies targeting il-6 and cd126 |
| SG11201809786TA SG11201809786TA (en) | 2016-05-05 | 2017-05-05 | Dna monoclonal antibodies targeting il-6 and cd126 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809786TA SG11201809786TA (en) | 2016-05-05 | 2017-05-05 | Dna monoclonal antibodies targeting il-6 and cd126 |
Country Status (12)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230111264A (ko) * | 2016-11-07 | 2023-07-25 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | 라임병에 사용하기 위한 dna 항체 작제물 |
| KR102635888B1 (ko) | 2019-03-19 | 2024-02-15 | 엘지전자 주식회사 | 공기청정기 |
| JP2024504614A (ja) * | 2021-01-14 | 2024-02-01 | トランスレイト バイオ， インコーポレイテッド | ｍＲＮＡがコードする抗体を送達する方法および組成物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1562968E (pt) * | 2001-11-14 | 2013-10-23 | Janssen Biotech Inc | Anticorpos anti-il-6, composições, métodos e utilizações |
| JO3058B1 (ar) * | 2005-04-29 | 2017-03-15 | Applied Molecular Evolution Inc | الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها |
| SI1960430T1 (sl) | 2005-12-09 | 2015-01-30 | Ucb Pharma, S.A. | Molekule protiteles s specifiäśnostjo za äśloveĺ ki il-6 |
| MX2009001110A (es) * | 2006-08-03 | 2009-05-11 | Vaccinex Inc | Anticuerpos monoclonales anti-il-6 y usos de los mismos. |
| US8034344B2 (en) | 2008-05-13 | 2011-10-11 | Novimmune S.A. | Anti-IL-6/IL-6R antibodies and methods of use thereof |
| WO2011084714A2 (en) | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
| US9304134B2 (en) | 2010-11-23 | 2016-04-05 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of anemia |
| AU2013358944B2 (en) * | 2012-12-13 | 2016-08-18 | Inovio Pharmaceuticals, Inc. | DNA antibody constructs and method of using same |
| IL312865B2 (en) * | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
-
2017
- 2017-05-05 EP EP17793405.6A patent/EP3452106A4/en active Pending
- 2017-05-05 KR KR1020257000876A patent/KR20250011241A/ko active Pending
- 2017-05-05 CA CA3023089A patent/CA3023089A1/en active Pending
- 2017-05-05 JP JP2019510567A patent/JP7311113B2/ja active Active
- 2017-05-05 AU AU2017261292A patent/AU2017261292B2/en active Active
- 2017-05-05 CN CN201780041454.5A patent/CN109789224A/zh active Pending
- 2017-05-05 SG SG10202011023YA patent/SG10202011023YA/en unknown
- 2017-05-05 BR BR112018072697-4A patent/BR112018072697A2/pt unknown
- 2017-05-05 WO PCT/US2017/031193 patent/WO2017192933A1/en unknown
- 2017-05-05 EA EA201892524A patent/EA201892524A1/ru unknown
- 2017-05-05 SG SG11201809786TA patent/SG11201809786TA/en unknown
- 2017-05-05 KR KR1020237013950A patent/KR20230058733A/ko not_active Ceased
- 2017-05-05 KR KR1020187035166A patent/KR20190031439A/ko not_active Ceased
- 2017-05-05 US US16/098,918 patent/US20190192692A1/en active Pending
- 2017-05-05 MX MX2018013523A patent/MX2018013523A/es unknown
-
2023
- 2023-03-28 JP JP2023051617A patent/JP2023086734A/ja active Pending
-
2024
- 2024-05-10 AU AU2024203109A patent/AU2024203109A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7311113B2 (ja) | 2023-07-19 |
| KR20230058733A (ko) | 2023-05-03 |
| KR20250011241A (ko) | 2025-01-21 |
| CA3023089A1 (en) | 2017-11-09 |
| AU2017261292A1 (en) | 2018-12-20 |
| EP3452106A1 (en) | 2019-03-13 |
| BR112018072697A2 (pt) | 2019-02-19 |
| MX2018013523A (es) | 2019-06-10 |
| EP3452106A4 (en) | 2020-01-08 |
| WO2017192933A1 (en) | 2017-11-09 |
| US20190192692A1 (en) | 2019-06-27 |
| AU2024203109A1 (en) | 2024-05-30 |
| SG11201809786TA (en) | 2018-12-28 |
| CN109789224A (zh) | 2019-05-21 |
| EA201892524A1 (ru) | 2019-04-30 |
| KR20190031439A (ko) | 2019-03-26 |
| JP2019518074A (ja) | 2019-06-27 |
| JP2023086734A (ja) | 2023-06-22 |
| AU2017261292B2 (en) | 2024-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275547A (en) | Antigen-binding proteins target co-antigens | |
| ZA202001285B (en) | Antigen-binding proteins targeting shared antigens | |
| IL291711A (en) | Anti-ctla-4 antibodies and methods of using them | |
| ZA201902533B (en) | Anti-pd-l1 antibodies and variants | |
| IL262092B (en) | Anti-pacap antibodies from humans and their use | |
| ZA201707138B (en) | Anti-ceacam6 antibodies and uses thereof | |
| ZA201701920B (en) | Anti-human il-17 monoclonal antibodies and use thereof | |
| IL253462A0 (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| IL256086A (en) | Anti-her2 antibodies and methods of use | |
| IL286208A (en) | Monoclonal antibodies of human origin and methods of using them | |
| LT3353212T (lt) | Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas | |
| IL254670A0 (en) | Human anti-c1s antibodies and methods of using them | |
| GB201506409D0 (en) | Humanized anti-axl antibodies and their conjugates | |
| ZA202003858B (en) | Monoclonal antibodies and methods for using same | |
| IL257323A (en) | New antibodies against human gpvi and their uses | |
| SG11201708624YA (en) | Therapeutic antibodies and uses thereof | |
| IL267271A (en) | Antibodies against il-5 | |
| SG10202011021XA (en) | Dna monoclonal antibodies targeting influenza virus | |
| SG10202011023YA (en) | Dna monoclonal antibodies targeting il-6 and cd126 | |
| IL266059A (en) | Anti-rankl antibodies and their uses | |
| GB201511196D0 (en) | Monoclonal antibodies | |
| GB201621446D0 (en) | IL-11 antibodies |